Androgen Deprivation Therapy (ADT) in 2026: Benefits, Risks and New Research in Prostate Cancer

By Editorial Team May 19, 2026

Prostate cancer is one of the most hormone-sensitive cancers in medicine. For decades, doctors have used androgen deprivation therapy (ADT) — also called hormone therapy — to slow or shrink prostate tumors by reducing testosterone levels.

For many men, ADT can be life-extending and highly effective. But there’s another side to the story.

Modern research shows that long-term testosterone suppression can affect nearly every system in the body — including the heart, brain, muscles, bones, metabolism and emotional health.

Today, ADT is increasingly viewed as a double-edged sword:

powerful against prostate cancer,
but potentially costly to long-term health and quality of life.

Here’s what the latest evidence says about ADT in 2026.

What Is Androgen Deprivation Therapy (ADT)?

Androgen deprivation therapy lowers male hormones — primarily testosterone and dihydrotestosterone (DHT) — that help prostate cancer cells grow.

Because many prostate tumors depend on androgen signaling, reducing testosterone can:

shrink tumors,
slow progression,
improve survival,
and enhance the effectiveness of radiation therapy.

ADT is commonly used for:

advanced prostate cancer,
metastatic prostate cancer,
recurrent disease,
high-risk localized cancer,
or alongside radiation therapy.

How ADT Works

The testes produce about 90–95% of testosterone in men.

ADT works by:

stopping testosterone production,
blocking androgen receptors,
or both.

Main Types of ADT

1. GnRH Agonists

These drugs suppress testosterone production after an initial testosterone “flare.”

Examples include:

leuprolide (Lupron),
goserelin,
triptorelin.

2. GnRH Antagonists

These lower testosterone more rapidly and may carry lower cardiovascular risk in some patients.

Examples:

degarelix,
relugolix.

3. Anti-Androgens

These block androgen receptors directly.

Examples:

bicalutamide,
enzalutamide,
apalutamide,
darolutamide.

4. Androgen Synthesis Inhibitors

These reduce androgen production throughout the body.

Example:

abiraterone.

5. Surgical Castration (Orchiectomy)

Removal of the testes permanently reduces testosterone production.

Although effective, this is used less commonly today due to psychological and quality-of-life concerns.

Why ADT Can Be So Effective

Testosterone acts like fuel for many prostate cancer cells.

By dramatically lowering testosterone:

tumor growth often slows,
PSA levels frequently drop,
symptoms may improve,
and survival can increase in selected patients.

ADT has become a backbone of treatment for:

metastatic hormone-sensitive prostate cancer,
biochemical recurrence,
and high-risk disease combined with radiation therapy.

In advanced disease, newer combinations using:

ADT + enzalutamide,
ADT + abiraterone,
or ADT + chemotherapy

have improved outcomes significantly compared with ADT alone.

The Hidden Cost of Testosterone Suppression

While ADT targets cancer cells, testosterone also plays critical roles throughout the body.

Low testosterone can affect:

muscle mass,
bone density,
metabolism,
cognition,
sexual health,
cardiovascular function,
and emotional well-being.

Many men describe ADT as:

“aging 20 years in a few months.”

Common ADT Side Effects

Hot Flashes

One of the most common symptoms.

Some men experience:

sudden sweating,
flushing,
nighttime overheating,
and sleep disruption.

Fatigue

ADT-related fatigue can become profound and persistent.

This may involve:

low motivation,
decreased endurance,
mental exhaustion,
and reduced physical activity.

Loss of Muscle and Weight Gain

Low testosterone promotes:

muscle loss,
increased body fat,
reduced strength,
and sarcopenia.

Many patients notice:

abdominal weight gain,
weaker legs,
reduced athletic capacity,
and worsening insulin resistance.

Sexual Dysfunction

ADT commonly causes:

loss of libido,
erectile dysfunction,
reduced sexual satisfaction,
infertility.

These effects can severely affect relationships and emotional health.

ADT and Cardiovascular Disease

One of the biggest shifts in recent years is recognition that cardiovascular disease may become a major competing risk during ADT.

Studies increasingly associate long-term ADT with:

insulin resistance,
metabolic syndrome,
diabetes,
dyslipidemia,
heart attack,
stroke,
and cardiovascular mortality.

Men with pre-existing:

hypertension,
obesity,
diabetes,
coronary artery disease

may be particularly vulnerable.

Some evidence suggests GnRH antagonists such as relugolix or degarelix may have lower cardiovascular risk compared with older GnRH agonists in selected patients.

Because of this, many experts now recommend:

cardiovascular screening,
glucose monitoring,
lipid monitoring,
exercise programs,
and cardio-oncology collaboration during ADT.

Brain Fog, Mood Changes and Cognitive Decline

This has become one of the most discussed ADT side effects online.

Some men report:

memory problems,
slower thinking,
reduced concentration,
emotional flattening,
depression,
and “brain fog.”

Research on dementia risk remains mixed.

Some studies suggest prolonged ADT exposure may increase the risk of:

cognitive impairment,
Alzheimer’s disease,
or dementia,

while others show weaker or inconsistent associations.

Still, the real-world cognitive effects experienced by many patients are increasingly recognized by clinicians.

Bone Loss and Osteoporosis

Testosterone helps maintain bone density.

Long-term ADT can accelerate:

osteoporosis,
fractures,
spinal compression fractures,
and frailty.

Bone protection strategies may include:

weight-bearing exercise,
resistance training,
vitamin D,
calcium,
bone density testing,
bisphosphonates,
or denosumab in selected patients.

Intermittent vs Continuous ADT

Not all men require continuous hormone suppression.

Intermittent ADT

This involves cycling on and off therapy based on:

PSA levels,
imaging,
symptoms,
and disease status.

Potential benefits:

improved quality of life,
partial testosterone recovery,
less fatigue,
fewer sexual side effects,
and reduced metabolic toxicity.

However, intermittent therapy is not appropriate for everyone.

Suitability depends on:

cancer stage,
tumor aggressiveness,
PSA kinetics,
and metastatic burden.

This remains an important discussion between patients and oncology teams.

When Prostate Cancer Stops Responding to ADT

Unfortunately, prostate cancer can evolve.

Over time, some tumors become:

Castration-Resistant Prostate Cancer (CRPC)

This means the cancer continues growing despite very low testosterone levels.

Cancer cells may adapt through:

androgen receptor amplification,
alternative hormone pathways,
intratumoral androgen production,
metabolic rewiring,
or neuroendocrine transformation.

Modern treatment strategies for CRPC may include:

enzalutamide,
abiraterone,
chemotherapy,
PARP inhibitors,
radioligand therapy,
PSMA-targeted therapy,
immunotherapy in selected cases.

Emerging Research: Is the Future Beyond Continuous Testosterone Suppression?

Researchers are increasingly exploring alternatives and refinements to traditional ADT.

Bipolar Androgen Therapy (BAT)

One surprising area of research involves cycling between:

very high testosterone,
and very low testosterone.

This approach, called Bipolar Androgen Therapy (BAT), may:

re-sensitize resistant tumors,
improve quality of life,
and reduce adaptive resistance in some patients.

Although still investigational in many settings, BAT highlights how prostate cancer biology may be more complex than simply “lower testosterone at all costs.”

How to Reduce ADT Side Effects

Lifestyle interventions can significantly improve quality of life during hormone therapy.

1. Resistance Training

One of the most effective ways to combat:

muscle loss,
insulin resistance,
fatigue,
and bone loss.

2. Aerobic Exercise

Walking, cycling and interval training may improve:

cardiovascular health,
fatigue,
mood,
and metabolic markers.

3. Mediterranean-Style Diet

Focus on:

vegetables,
olive oil,
legumes,
fish,
berries,
nuts,
and high-fiber foods.

Limiting ultra-processed foods and excess sugar may help reduce metabolic dysfunction.

4. Bone Health Monitoring

Important strategies include:

vitamin D optimization,
calcium intake,
DEXA scans,
and fall prevention.

5. Cognitive Support

Helpful approaches may include:

sleep optimization,
stress reduction,
social engagement,
cognitive exercises,
meditation,
and regular physical activity.

Questions Patients Should Ask Before Starting ADT

How long will I need ADT?
Is intermittent therapy an option?
What cardiovascular risks do I already have?
How can I protect muscle and bone health?
Should I see a cardiologist?
What symptoms should I monitor?
Are newer agents appropriate for my cancer type?
What happens if the cancer becomes resistant?

Final Thoughts

Androgen deprivation therapy remains one of the most important treatments in prostate cancer.

For many men, it can:

prolong survival,
improve cancer control,
and reduce symptoms.

But ADT is no longer viewed as a simple or benign treatment.

Modern evidence increasingly shows that long-term testosterone suppression can affect:

metabolism,
cardiovascular health,
cognition,
muscle,
bone,
and overall quality of life.

The future of prostate cancer care is likely to involve:

more personalized hormone strategies,
smarter sequencing,
better supportive care,
precision oncology,
and integrated lifestyle medicine.

For patients facing ADT, understanding both the benefits and the tradeoffs is essential.